High-density lipoprotein: gene-based approaches to the prevention of atherosclerosis

被引:14
作者
Rong, JX
Fisher, EA
机构
[1] CUNY Mt Sinai Sch Med, Zena & Michael Wiener Cardiovasc Inst, Dept Med, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Zena & Michael Wiener Cardiovasc Inst, Lab Lipoprot Res, New York, NY 10029 USA
关键词
atherosclerosis; gene therapy; high-density lipoprotein metabolism;
D O I
10.3109/07853890009002035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although the atheroprotective role of high-density lipoprotein (HDL) has been well documented in epidemiological and animal studies, highly effective therapeutic approaches for the selective increase of plasma HDL levels or function are not yet available. Several mechanisms by which HDL exerts an atheroprotective effect have been proposed on the basis of experiments in vitro and in vivo. These mechanisms include directing excess cellular cholesterol from the peripheral tissues to the liver in 'reverse cholesterol transport', inhibiting oxidative modification or aggregation of LDL, and modulating inflammatory responses to favour vasoprotection. This review gives an overview of the genes regulating these mechanisms, such as those encoding apolipoprotein AT, lecithin:cholesterol acyltransferase (LCAT), scavenger receptor B1 (SR-BI), and the ATP-binding cassette transporter 1 (ABC1), and the potential to exploit them to develop gene-based therapeutic approaches to increase the level or function of HDL.
引用
收藏
页码:642 / 651
页数:10
相关论文
共 73 条
[51]   Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention [J].
Rader, DJ ;
Maugeais, C .
MOLECULAR MEDICINE TODAY, 2000, 6 (04) :170-175
[52]   INHIBITION OF EARLY ATHEROGENESIS IN TRANSGENIC MICE BY HUMAN APOLIPOPROTEIN-A-I [J].
RUBIN, EM ;
KRAUSS, RM ;
SPANGLER, EA ;
VERSTUYFT, JG ;
CLIFT, SM .
NATURE, 1991, 353 (6341) :265-267
[53]   GLN-ARG192 POLYMORPHISM OF PARAOXONASE AND CORONARY HEART-DISEASE IN TYPE-2 DIABETES [J].
RUIZ, J ;
BLANCHE, H ;
JAMES, RW ;
GARIN, MCB ;
VAISSE, C ;
CHARPENTIER, G ;
COHEN, N ;
MORABIA, A ;
PASSA, P ;
FROGUEL, P .
LANCET, 1995, 346 (8979) :869-872
[54]   Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 [J].
Rust, S ;
Rosier, M ;
Funke, H ;
Real, J ;
Amoura, Z ;
Piette, JC ;
Deleuze, JF ;
Brewer, HB ;
Duverger, N ;
Denèfle, P ;
Assmann, G .
NATURE GENETICS, 1999, 22 (04) :352-355
[55]   Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene - Generation of a new animal model for human LCAT deficiency [J].
Sakai, N ;
Vaisman, BL ;
Koch, CA ;
Hoyt, RF ;
Meyn, SM ;
Talley, GD ;
Paiz, JA ;
Brewer, HB ;
SantamarinaFojo, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (11) :7506-7510
[56]   CORONARY HEART-DISEASE PREVALENCE AND OTHER CLINICAL-FEATURES IN FAMILIAL HIGH-DENSITY LIPOPROTEIN DEFICIENCY (TANGIER DISEASE) [J].
SCHAEFER, EJ ;
ZECH, LA ;
SCHWARTZ, DE ;
BREWER, HB .
ANNALS OF INTERNAL MEDICINE, 1980, 93 (02) :261-266
[57]   Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene [J].
SeguretMace, S ;
LattaMahieu, M ;
Castro, G ;
Luc, G ;
Fruchart, JC ;
Rubin, E ;
Denefle, P ;
Duverger, N .
CIRCULATION, 1996, 94 (09) :2177-2184
[58]   Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis [J].
Shih, DM ;
Gu, LJ ;
Xia, YR ;
Navab, M ;
Li, WF ;
Hama, S ;
Castellani, LW ;
Furlong, CE ;
Costa, LG ;
Fogelman, AM ;
Lusis, AJ .
NATURE, 1998, 394 (6690) :284-287
[59]   Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis [J].
Shih, DM ;
Xia, YR ;
Wang, XP ;
Miller, E ;
Castellani, LW ;
Subbanagounder, G ;
Cheroutre, H ;
Faull, KF ;
Berliner, JA ;
Witztum, JL ;
Lusis, AJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (23) :17527-17535
[60]  
TALL A, 1996, ATHEROSCLEROSIS CORO, V1, P105